Literature DB >> 19373869

Modulation of HSP27 alters hypoxia-induced endothelial permeability and related signaling pathways.

Tiegang Liu1, Oscar E Guevara, Rod R Warburton, Nicholas S Hill, Matthias Gaestel, Usamah S Kayyali.   

Abstract

This manuscript describes how the permeability of pulmonary artery microvascular endothelial cell (RPMEC) monolayer is elevated by hypoxia and the role played by HSP27 phosphorylation. p38 MAP kinase activation leading to HSP27 phosphorylation was previously shown by our laboratory to alter the actin cytoskeleton and tethering properties of RPMEC. This effect was independent of hypoxia-induced contractility which was ROCK-dependent rather than HSP27-dependent. Results described here show that increased HSP27 phosphorylation not only does not underlie hypoxia-induced permeability, but may actually augment the endothelial barrier. Hypoxia causes gap formation between RPMEC and increases MLC2 phosphorylation. The phosphorylation of MYPT1, which inhibits MLC2 phosphatase, is also increased in hypoxia. In addition, FAK phosphorylation, which alters focal adhesion signaling, is increased in hypoxia. Overexpressing phosphomimicking HSP27 (pmHSP27), which induces significant actin stress fiber formation, surprisingly renders RPMEC resistant to hypoxia- or TGFbeta-induced permeability. siRNA against pmHSP27 reverses the increased actin stress fiber formation in pmHSP27-overexpressing cells, and disrupting actin stress fibers in pmHSP27-overexpressing RPMEC renders them more susceptible to hypoxia. Finally, hypoxia-induced gap formation, as well as phosphorylation of MLC2, MYPT1 and FAK are almost abolished by overexpressing pmHSP27 in RPMEC. These effects of pmHSP27 overexpression might represent decreased cytoskeletal plasticity and increased tethering which counteracts permeability-inducing contractility. Thus hypoxia activates two pathways one leading to contractility and increased permeability, the other leading to actin stress fibers, stronger adhesion, and reduced permeability. Altering HSP27 phosphorylation, which tips the balance towards decreased permeability, might be targeted in managing endothelial barrier dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19373869      PMCID: PMC2891512          DOI: 10.1002/jcp.21773

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  60 in total

1.  Protection against hypoxia-induced increase in blood-brain barrier permeability: role of tight junction proteins and NFkappaB.

Authors:  Rachel C Brown; Karen S Mark; Richard D Egleton; Jason D Huber; Amanda R Burroughs; Thomas P Davis
Journal:  J Cell Sci       Date:  2003-02-15       Impact factor: 5.285

2.  Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2.

Authors:  Usamah S Kayyali; Corin M Pennella; Carolina Trujillo; Otto Villa; Matthias Gaestel; Paul M Hassoun
Journal:  J Biol Chem       Date:  2002-08-28       Impact factor: 5.157

3.  Provision of phosphorylatable substrate during hypoxia decreases jejunal barrier function.

Authors:  Kelly A Tappenden
Journal:  Nutrition       Date:  2002-02       Impact factor: 4.008

4.  Hypoxia-induced increases in pulmonary transvascular protein escape in rats. Modulation by glucocorticoids.

Authors:  T J Stelzner; R F O'Brien; K Sato; J V Weil
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  p38 MAPK activation by TGF-beta1 increases MLC phosphorylation and endothelial monolayer permeability.

Authors:  Peter L Goldberg; Darren E MacNaughton; Richard T Clements; Fred L Minnear; Peter A Vincent
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-01       Impact factor: 5.464

6.  Endothelial contraction and monolayer hyperpermeability are regulated by Src kinase.

Authors:  David R Mucha; Carter L Myers; Richard C Schaeffer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11-27       Impact factor: 4.733

7.  Hypoxia inhibits myosin phosphatase in pulmonary arterial smooth muscle cells: role of Rho-kinase.

Authors:  Zhiqian Wang; M Carita Lanner; Najia Jin; Darl Swartz; Liang Li; Rodney A Rhoades
Journal:  Am J Respir Cell Mol Biol       Date:  2003-04-24       Impact factor: 6.914

8.  Modulatory role of focal adhesion kinase in regulating human pulmonary arterial endothelial barrier function.

Authors:  Dolly Mehta; Chinnaswamy Tiruppathi; Raudal Sandoval; Richard D Minshall; Michael Holinstat; Asrar B Malik
Journal:  J Physiol       Date:  2002-03-15       Impact factor: 5.182

9.  Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase.

Authors:  Steven M Dudek; Jeffrey R Jacobson; Eddie T Chiang; Konstantin G Birukov; Peiyi Wang; Xi Zhan; Joe G N Garcia
Journal:  J Biol Chem       Date:  2004-03-31       Impact factor: 5.157

10.  Factors influencing the expression of stress fibers in vascular endothelial cells in situ.

Authors:  G E White; M A Gimbrone; K Fujiwara
Journal:  J Cell Biol       Date:  1983-08       Impact factor: 10.539

View more
  14 in total

1.  Role of src-suppressed C kinase substrate in rat pulmonary microvascular endothelial hyperpermeability stimulated by inflammatory cytokines.

Authors:  Qing-Hai You; Geng-Yun Sun; Nan Wang; Shan Chen; Qing-Li Luo
Journal:  Inflamm Res       Date:  2010-05-08       Impact factor: 4.575

2.  Primary cilia regulates the directional migration and barrier integrity of endothelial cells through the modulation of hsp27 dependent actin cytoskeletal organization.

Authors:  Thomas J Jones; Ravi K Adapala; Werner J Geldenhuys; Chris Bursley; Wissam A AbouAlaiwi; Surya M Nauli; Charles K Thodeti
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

3.  Anthrax lethal toxin-induced lung injury and treatment by activating MK2.

Authors:  Tiegang Liu; Rod R Warburton; Nicholas S Hill; Usamah S Kayyali
Journal:  J Appl Physiol (1985)       Date:  2015-06-11

4.  Anthrax lethal toxin disrupts the endothelial permeability barrier through blocking p38 signaling.

Authors:  Tiegang Liu; Erica Milia; Rod R Warburton; Nicholas S Hill; Matthias Gaestel; Usamah S Kayyali
Journal:  J Cell Physiol       Date:  2012-04       Impact factor: 6.384

5.  Regulation of vimentin intermediate filaments in endothelial cells by hypoxia.

Authors:  Tiegang Liu; Oscar E Guevara; Rod R Warburton; Nicholas S Hill; Matthias Gaestel; Usamah S Kayyali
Journal:  Am J Physiol Cell Physiol       Date:  2010-04-28       Impact factor: 4.249

6.  Intermittent hypoxia-induced endothelial barrier dysfunction requires ROS-dependent MAP kinase activation.

Authors:  Vladislav V Makarenko; Peter V Usatyuk; Guoxiang Yuan; May M Lee; Jayasri Nanduri; Viswanathan Natarajan; Ganesh K Kumar; Nanduri R Prabhakar
Journal:  Am J Physiol Cell Physiol       Date:  2014-01-29       Impact factor: 4.249

7.  A combined proteomic and transcriptomic approach shows diverging molecular mechanisms in thoracic aortic aneurysm development in patients with tricuspid- and bicuspid aortic valve.

Authors:  Sanela Kjellqvist; Shohreh Maleki; Therese Olsson; Maggy Chwastyniak; Rui Miguel Mamede Branca; Janne Lehtiö; Florence Pinet; Anders Franco-Cereceda; Per Eriksson
Journal:  Mol Cell Proteomics       Date:  2012-11-26       Impact factor: 5.911

8.  Nerve Root Compression Increases Spinal Astrocytic Vimentin in Parallel With Sustained Pain and Endothelial Vimentin in Association With Spinal Vascular Reestablishment.

Authors:  Jenell R Smith; Jasmine Lee; Beth A Winkelstein
Journal:  Spine (Phila Pa 1976)       Date:  2017-10-01       Impact factor: 3.241

Review 9.  Hypoxia and the modulation of the actin cytoskeleton - emerging interrelations.

Authors:  Anke Zieseniss
Journal:  Hypoxia (Auckl)       Date:  2014-03-25

10.  Hypoxia-induced hyperpermeability of rat glomerular endothelial cells involves HIF-2α mediated changes in the expression of occludin and ZO-1.

Authors:  Peng-Li Luo; Yan-Jun Wang; Yan-Yan Yang; Jia-Jia Yang
Journal:  Braz J Med Biol Res       Date:  2018-05-17       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.